VEGF

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
среда, ноября 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, VEGF, TAK, RAS, PDUFA, Food, Colorectal Cancer Alliance, MAA, Priority, JAMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Priority review, PMDA, Colorectal cancer, CRC, EMA, FACP, Cancer, Metastasis, Patient, Diagnosis, Vanderbilt University Medical Center, Pharmaceutical industry, Takeda, EU, Lancet

"There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.

Key Points: 
  • "There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.
  • “For far too long, healthcare providers and patients have had limited options when selecting a therapy for metastatic colorectal cancer.
  • The trials investigated FRUZAQLA plus best supportive care versus placebo plus best supportive care in patients with previously treated mCRC.
  • “Colorectal cancer is a highly heterogeneous disease, making it difficult to bring advancements to patients whose cancer has metastasized.

Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Retrieved on: 
вторник, октября 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TKI, Patient, HKEX, Research, VEGF, SMMT, NSCLC, Drug discovery, Lung cancer, PD-1, Doctor of Philosophy, Summit, Poster, Senior, Phase, SITC, Immunotherapy, Paranal Observatory, Tumor microenvironment, Safety, Society, TME, EGFR, Pharmaceutical industry

The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time.

Key Points: 
  • The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time.
  • The poster is a collaborative effort between Summit and our collaboration and licensing partner, Akeso, Inc. (HKEX Code: 9926.HK), who generated and analyzed the data.
  • The poster describes how ivonescimab displays unique cooperative binding to each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.
  • Lung cancer is believed to impact approximately 238,0004 people in the United States each year and approximately 477,0005 in Europe.

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

Retrieved on: 
понедельник, октября 23, 2023
FDA, VEGF, CST, AAV, Intravitreal injection, PRISM, AMD, DME, European Medicines Agency, SAE, Diabetic retinopathy, EMA, Safety, Intraocular pressure, Patient, Anti-VEGF, Vaccine, Pharmaceutical industry, Placental growth factor

PRIME designation is granted by the EMA to enhance support for the development of medicines that target an unmet medical need and offers the opportunity to accelerate review of the marketing applications to bring such medicines to patients sooner.

Key Points: 
  • PRIME designation is granted by the EMA to enhance support for the development of medicines that target an unmet medical need and offers the opportunity to accelerate review of the marketing applications to bring such medicines to patients sooner.
  • The designation follows positive interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile.
  • “We are thrilled that the EMA has awarded PRIME designation to intravitreal 4D-150,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • We are efficiently advancing 4D-150 development for treatment of both wet AMD and DME patients, both of which represent large market opportunities.

Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

Retrieved on: 
вторник, октября 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Physician, BAL, VEGF, BRAF, Standard of care, Inc., EGFR, Safety, Survival, CRC, BOT, FDA, ESMO, Immunotherapy, Nursing, Biologics license application, Oxaliplatin, Fast Track, Irinotecan, Patient, Pharmaceutical industry

The phase 2 study follows an expanded phase 1 study of over 100 patients with a median of four prior lines of therapy and with 25% having failed previous immunotherapy.

Key Points: 
  • The phase 2 study follows an expanded phase 1 study of over 100 patients with a median of four prior lines of therapy and with 25% having failed previous immunotherapy.
  • At ESMO GI earlier this year, data from the phase 1 study were presented.
  • "Our gratitude goes out to the patients, care partners, physicians, and nurses involved in this trial, as we push forward with BOT/BAL to bridge vital gaps in cancer care."
  • The totality of data from the phase 1 and 2 studies will contribute to a planned Biologics License Application to the U.S. FDA in 2024.

The Retinal Degeneration Fund Announces an Investment in NVasc

Retrieved on: 
понедельник, октября 16, 2023
Acquisition, Doctor of Philosophy, Visual impairment, VEGF, Survival, Disease, IL-6, AMD, Nobel, Leukemia inhibitory factor, Growth, Colic flexures, Cytokine, Lasker, Research, Geographic atrophy, Pharmaceutical industry, MD

RALEIGH, N.C., Oct. 16, 2023 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research to advance preventions, treatments, and cures for retinal degenerative diseases, announces an investment in NVasc, an early-stage company focused on treating age-related macular degeneration (AMD).

Key Points: 
  • RALEIGH, N.C., Oct. 16, 2023 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research to advance preventions, treatments, and cures for retinal degenerative diseases, announces an investment in NVasc, an early-stage company focused on treating age-related macular degeneration (AMD).
  • The financing supports continued product and nonclinical development of NVasc's technology for therapeutic angiogenesis as a treatment for retinal ischemia associated with age-related macular degeneration and geographic atrophy.
  • Adrienne Graves, PhD, RD Fund Chair, joined the NVasc board as an independent board director.
  • Dr. Graves, chair of Iveric Bio prior to its acquisition by Astellas, brings a wealth of Board governance experience to NVasc."

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Retrieved on: 
вторник, сентября 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Workforce, Bevacizumab, Commercialization, Doctor of Philosophy, Lymphoid leukemia, Food, Medicines and Healthcare products Regulatory Agency, Calendar, Clinical trial, Cancer, OXPHOS, Aplastic anemia, Medication, Pharmaceuticals and Medical Devices Agency, Acute myeloid leukemia, PI3K, Kyowa Kirin, Development, VEGF, AML, BCL2, Glycolysis, Patient, Investment, PMDA, Colorectal cancer, Neoplasm, MEI, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, CDK9, Venetoclax, Safety, Pharmaceutical industry, Cryptocurrency, Shareholder

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.

Key Points: 
  • MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.
  • The certified results showed that 59.70% of outstanding shares were voted, of which 47.86% voted in favor of the proposed transaction, and 51.44% against.
  • In May 2023, MEI regained compliance with the Nasdaq minimum bid requirement after the Company implemented a 1-for-20 reverse stock split in April 2023.
  • As of June 30, 2023, MEI had $100.7 million in cash, cash equivalents, and short-term investments with no outstanding debt.

4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD

Retrieved on: 
четверг, сентября 7, 2023
PRISM, Injection, Diabetes, DME, AMD, Clinical trial, Paratriathlon, Diabetic retinopathy, VEGF, Patient, Ophthalmology, FDA, Pharmaceutical industry

“We are delighted to be advancing 4D-150 in our Phase 2 SPECTRA clinical trial in patients with DME, and to further study intravitreal 4D-150 in a broader patient population in wet AMD,” said Robert Kim, M.D., Chief Medical Officer of 4DMT.

Key Points: 
  • “We are delighted to be advancing 4D-150 in our Phase 2 SPECTRA clinical trial in patients with DME, and to further study intravitreal 4D-150 in a broader patient population in wet AMD,” said Robert Kim, M.D., Chief Medical Officer of 4DMT.
  • “DME is a major cause of vision loss among people with diabetes and may lead to blindness.
  • “DME is an important opportunity for 4DMT, and we believe 4D-150’s differentiated profile in wet AMD will drive interest and strong enrollment in the SPECTRA trial.
  • Importantly, we intend to include a broad wet AMD patient population in pivotal Phase 3 clinical trials with 4D-150.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
понедельник, сентября 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
понедельник, сентября 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
пятница, сентября 8, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 8, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.